Avdoralimab (Anti-C5aR1 mAb) Versus Placebo in Patients With Severe COVID-19: Results From a Randomized Controlled Trial (FOR COVID Elimination [FORCE])*
CONCLUSIONS:
In this randomized trial in hospitalized patients with severe COVID-19 pneumonia, avdoralimab did not significantly improve clinical status at days 14 and 28 (funded by Innate Pharma, ClinicalTrials.gov number, NCT04371367).
Source: Critical Care Medicine - Category: Emergency Medicine Tags: Clinical Investigations Source Type: research
More News: COVID-19 | Emergency Medicine | France Health | International Medicine & Public Health | Pharmaceuticals | Pneumonia | Study | WHO